Metabotypes of response to bariatric surgery independent of the magnitude of weight loss

PLoS One. 2018 Jun 1;13(6):e0198214. doi: 10.1371/journal.pone.0198214. eCollection 2018.

Abstract

Objective: Bariatric surgery is considered the most efficient treatment for morbid obesity and its related diseases. However, its role as a metabolic modifier is not well understood. We aimed to determine biosignatures of response to bariatric surgery and elucidate short-term metabolic adaptations.

Methods: We used a LC- and FIA-ESI-MS/MS approach to quantify acylcarnitines, (lyso)phosphatidylcholines, sphingomyelins, amino acids, biogenic amines and hexoses in serum samples of subjects with morbid obesity (n = 39) before and 1, 3 and 6 months after bariatric surgery. K-means cluster analysis allowed to distinguish metabotypes of response to bariatric surgery.

Results: For the first time, global metabolic changes following bariatric surgery independent of the baseline health status of the subjects have been revealed. We identify two metabolic phenotypes (metabotypes) at the interval 6 months-baseline after surgery, which presented differences in the levels of compounds of urea metabolism, gluconeogenic precursors and (lyso)phospholipid particles. Clinically, metabotypes were different in terms of the degree of improvement in insulin resistance, cholesterol, low-density lipoproteins and uric acid independent of the magnitude of weight loss.

Conclusions: This study opens new perspectives and new hypotheses on the metabolic benefits of bariatric surgery and understanding of the biology of obesity and its associated diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anthropometry
  • Bariatric Surgery*
  • C-Reactive Protein / analysis
  • Chromatography, Liquid
  • Female
  • Follow-Up Studies
  • Gluconeogenesis
  • Humans
  • Insulin Resistance
  • Leptin / blood
  • Lipids / blood
  • Lipoproteins, LDL / metabolism
  • Male
  • Metabolome*
  • Middle Aged
  • Obesity, Morbid / blood
  • Obesity, Morbid / metabolism*
  • Obesity, Morbid / surgery
  • Phenotype*
  • Tandem Mass Spectrometry
  • Treatment Outcome
  • Urea / metabolism
  • Weight Loss / physiology*
  • Young Adult

Substances

  • LEP protein, human
  • Leptin
  • Lipids
  • Lipoproteins, LDL
  • Urea
  • C-Reactive Protein

Grants and funding

This research was supported by Project PI13/01172 (Plan N de I+D+i 2013-2016), co-funded by ISCIII-Subdirección General de Evaluación y Fomento de la Investigación; Project PI-0557-2013, co-funded by Fundación Progreso y Salud, Consejería de Salud y Bienestar Social, Junta de Andalucía, CIBERfes and CIBERobn, co-funded by Fondo Europeo de Desarrollo Regional (FEDER) and MTM2015/64465-C2-1-R (MINECO/FEDER). 2017 SGR 1546 and 2017 SGR 622 award from Generalitat de Catalunya’s Agency AGAUR. MPR acknowledges the APIF fellowship [INSA-UB]; ST and AMR acknowledge the Juan de la Cierva fellowship [MINECO] and BRM acknowledges the Sara Borrell postdoctoral fellowship, ISCIII, Spain (CD16/0003).